Hearts and Minds Faces NTA Drag as Corporate Travel Writedown Signals Portfolio Stress and Rotation Risks

The reported decline in Hearts and Minds' Net Tangible Assets (NTA) is a stark reflection of concentrated portfolio stress. The fund's Pre-Tax NTA stood at $3.37 per share in May 2020, a level that has since eroded. The most recent weekly estimate, as of March 16, 2026, shows a significant drop, though the exact figure is not provided in the evidence. This decline is not an isolated accounting adjustment but a direct consequence of severe portfolio performance.

The fund's portfolio fell 5% in February, a sharp correction that significantly underperformed the broader market's 1.3% decline. This divergence highlights the fund's vulnerability to specific sector headwinds, particularly the broad weakness in global software stocks and a rotation away from high-multiple growth names. The primary driver of the recent NTA pressure is a conservative accounting move: the fund has written down its entire stake in Corporate Travel to zero. This decision followed the stock's suspension in August 2025 amid an accounting probe, which revealed revenues had been overstated and a $162 million refund to customers was required. In the absence of an observable market price, the fund adopted a very conservative position, carrying the holding at zero.

This writedown marks the second time this year the fund has written a position to zero, following its write-off of the Opthea biotech investment in April. The move is a prudent, if painful, reflection of the asset's impaired value and liquidity. While the fund notes that the holding could realize value over time, the current valuation approach is a direct drag on the NTA. For institutional investors, this raises a critical question: is this a temporary event tied to a single, illiquid security, or a sign of deeper structural change in the fund's portfolio quality? The timing-coming on the heels of a 5% portfolio drop and amid a sector rotation-suggests the latter. The NTA decline is less a one-off accounting entry and more a symptom of a portfolio under pressure from both specific security failures and broader market shifts.

Portfolio Rotation and the Quality Factor

The recent 5% portfolio decline is not an isolated event but the visible outcome of a deliberate, if painful, strategic rotation. The fund is moving decisively away from the high-multiple growth names that have been under severe pressure, a shift driven by clear valuation concerns. The primary catalyst is investor anxiety over how rapid advances in artificial intelligence, particularly the rise of capable AI agents, could disrupt traditional software-as-a-service business models. This is a defensive reallocation, a response to a specific, powerful market narrative that has challenged the growth assumptions baked into many tech valuations.

This rotation is a classic quality factor play. By shedding positions in vulnerable software names, the fund is attempting to rebuild a portfolio with more durable cash flows and a lower beta to technology sector volatility. The recent additions of Cameco and Royalty Pharma exemplify this new direction. Both are cyclical, income-generating assets-Cameco in the energy sector and Royalty Pharma in the biotech royalty space. This alters the portfolio's risk profile, shifting it from a pure growth tilt to a more balanced, value-oriented mix that includes exposure to commodity cycles and royalty streams.

The strategic rationale is sound, but it comes with a fixed cost that does not adjust with performance. The fund's structure, which donates 1.5% of net assets each year to support Australian medical research, represents a permanent drag on returns. This fixed philanthropic commitment means that any underperformance in the portfolio is not offset by a reduction in expenses, compressing the net return available to shareholders. It is a structural choice that prioritizes social impact but removes a key lever for managing downside risk.

The impact on the fund's risk-adjusted return profile is mixed. On one hand, the rotation away from overvalued growth should improve downside protection and potentially enhance the portfolio's Sharpe ratio if the new holdings generate more stable returns. On the other, the move introduces new sector-specific risks and may sacrifice some of the high-growth potential that once defined the fund. The bottom line is that this is a portfolio construction decision with clear trade-offs. The fund is betting that the quality and income from its new holdings will provide a better risk-adjusted return over the medium term, even as it navigates a period of significant asset value write-downs.

Financial Impact and Valuation Metrics

The recent NTA decline is now translating into tangible pressure on the fund's profitability. The trailing net profit margin has fallen to 44.7% from 67.1% a year earlier. This compression is a direct consequence of the portfolio's current performance, which includes the significant write-down of the Corporate Travel stake and the broader 5% portfolio drop. While the fund remains profitable, with trailing twelve-month net income of A$19.4 million, the margin contraction signals that the earnings engine is being strained by asset value impairments and a challenging market environment for its core holdings.

On a valuation basis, the stock trades at a rich multiple. With a market cap of approximately $641 million and 225 million shares outstanding, the shares are priced at a forward P/E of 35x. This multiple implies significant confidence in future earnings growth. However, it sits in stark contrast to the fund's underlying asset base. The Pre-Tax NTA, which stood at $3.37 per share in May 2020, has since eroded. The current share price of around A$2.80 suggests a discount to that historical NTA level, but the magnitude of the discount is unclear from the evidence. The key risk is that this premium valuation is not sustainable if the NTA discount narrows due to further portfolio write-downs or if earnings growth falters. The fixed 1.5% annual donation to medical research also acts as a permanent drag on net returns, making it harder for the fund to deliver the top-line growth needed to justify its current rich multiple. For institutional investors, the setup is one of high expectations priced in, with the quality of earnings and the stability of the NTA now under the microscope.

Catalysts and Risks: Portfolio Re-alignment Watchpoints

The path forward for Hearts and Minds hinges on a few critical, near-term events that will determine whether the current NTA decline is a temporary discount or a structural warning. The most immediate catalyst is the resolution of the Corporate Travel situation. The fund's writedown to zero is a conservative accounting stance, but the potential for a trading restart and a subsequent valuation reassessment represents a binary event. The fund itself notes that a recommencement of trading at the halt price would have a positive impact on pre-tax NTA of 9 cents per share. While the company has provided an update and expects a further review, there is no set time frame for trading to recommence. This uncertainty is a direct liquidity and credit quality risk; until the probe is resolved and the stock trades, the fund's asset base remains impaired.

Beyond this specific event, the fund's ability to generate consistent pre-tax investment returns above 20% is the fundamental metric to watch. This level of return is necessary to support its fully franked dividend yield of about 6.6% and to justify its premium valuation. The fund's recent track record shows volatility: it posted a 32% pre-tax investment return over the past year and a 9.77% annualised pre-tax return since inception. However, the portfolio's 5% decline in February underlines the current pressure. Institutional investors must monitor whether the new portfolio construction-shifting toward cyclical, income-generating assets like Cameco and Royalty Pharma-can deliver the required risk-adjusted returns. A sustained failure to clear this hurdle would validate the NTA discount and challenge the fund's entire investment thesis.

Finally, any shift in the fund's donation policy or fee structure would be a structural change to its capital allocation model. The current arrangement, which donates 1.5% of net assets each year to medical research instead of charging management fees, is a fixed cost that compresses net returns. For now, this is a stable, mission-driven commitment. But if the fund's performance deteriorates further, pressure could build to alter this policy. Any such change would be a material signal about the fund's financial health and its ability to fund its social mission without eroding shareholder value. Until then, the watchpoints remain clear: resolve Corporate Travel, deliver on the return target, and maintain the status quo on capital allocation.